Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C) and golimumab (G), are used to treat the following conditions :
FDA-approved Indications (alphabetical list)
The tumor necrosis factor (TNF)-alpha inhibitors, including etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab, all bind to the cytokine TNF and inhibit its interaction with the TNF receptors . As a cytokine, TNF is involved with the inflammatory and immune response and can bind to TNF receptor 1 (TNFR1) or TNF receptor 2 (TNFR2) . It occurs in numerous forms, both monomeric and trimeric, as well as soluble and transmembrane. Upon binding, TNF triggers the activation of numerous pathways including the NFkB and MAPK pathways. This leads to the production of numerous inflammatory cytokines and can also lead to TNF-induced apoptotic pathway initiation. Etanercept is a fusion protein of two TNFR2 receptor extracellular domains and the Fc fragment of human IgG1 . It inhibits the binding of both TNF-alpha and TNF-beta to cell surface TNFRs. Infliximab is a chimeric monoclonal antibody that includes a murine variable region and constant human region . It binds to the soluble and transmembrane forms of TNF-alpha and inhibits the binding of TNF-alpha to TNFR. Adalimumab and golimumab are fully human monoclonal antibodies against TNF-alpha and, like infliximab, these antibodies bind to TNF-alpha and inhibit its binding to TNFR. Certolizumab is a humanized Fab fragment conjugated to polyethylene glycol (PEG).
Etanercept is administered subcutaneously. The injection sites should be rotated and given at least one inch apart from previous injection sites.
Infliximab is administered as an infusion. The infusion should occur over a period of 2 hours and should not be co-administered with other agents. Infusion-related reactions are possible, and if necessary, antihistamines, acetaminophen, and corticosteroids can be used to treat these reactions.
Adalimumab is administered by subcutaneous injection. The injection sites should be rotated and away from previous injection sites.
Certolizumab pegol is subcutaneously administered into the thigh or abdomen.
Golimumab can be administered intravenously (IV) or subcutaneously. Infusions should occur over a period of 30 minutes and should not be co-administered with any other agents. Subcutaneous injections are administered using an autoinjector.
The following adverse effects (AEs) were observed in greater than 10% of patients receiving a TNF-alpha inhibitor, including etanercept, infliximab, adalimumab, certolizumab pegol and golimumab .
Central Nervous System-related AEs: Headache
Dermatology-related AEs: Skin rash
Gastrointestinal-related AEs: Abdominal pain, nausea, diarrhea
Hematology-related AEs: Anemia
Hepatic-related AEs: Increased serum ALT
Immunology-related AEs: Increased ANA titer (~50%), antibody development
Infection-related AEs: Infection, including serious infection and abscess
Respiratory-related AEs: Upper respiratory tract infections, sinusitis, cough, pharyngitis
Miscellaneous AEs: Infusion-related reaction, injection site reactions
Other serious concerns related to AEs: Anaphylaxis and hypersensitivity reactions, autoimmune disorders, demyelinating CNS disease, heart failure, aplastic anemia, pancytopenia, reactivation of hepatitis B, leukopenia, neutropenia
US boxed warnings (for all TNF-alpha inhibitors):
Malignancy: Malignancies, including lymphoma, have been reported in patients receiving TNF alpha inhibitors. The malignancies arose approximately 30 months (ranging from 1 month to 84 months) after the first dose of the TNF alpha inhibitor and many of the cases were in pediatric and young adult populations. Additionally, cases of hepatosplenic T-cell lymphoma have been reported in the postmarketing period for adolescent males with either ulcerative colitis or Crohn disease.
Tuberculosis: Active tuberculosis or the reactivation of latent tuberculosis has been reported in patients receiving TNF-alpha inhibitors. Patients should be evaluated for the presence of tuberculosis before the initiation of therapy with TNF alpha inhibitors and treatment with antimycobacterial therapy should be initiated if latent tuberculosis is found. In cases of reactivation of latent tuberculosis, the reactivation occurs within the first few months of treatment with TNF-alpha inhibitors.
Infection: Patients receiving treatment with a TNF-alpha inhibitor are at heightened risk of developing serious or fatal infections. This occurred more commonly in patients that are receiving treatment with other immunosuppressive agents including methotrexate and corticosteroids. The types of infections include fungal infections, such as aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis and pneumocystosis, and bacterial and viral infections. In particular, legionellosis and listeriosis have been reported. Patients should be monitored for signs of infection and treatment with TNF-alpha inhibitors should be discontinued if serious infection or sepsis occurs. Empiric antifungal therapy should be considered in patients who are at increased risk of invasive fungal infections.
Etanercept: Do not administer to patients with sepsis.
Infliximab: Do not administer to patients with hypersensitivity to infliximab or murine proteins.
Adalimumab: None listed
Certolizumab pegol: None listed
Golimumab: None listed
Monitoring of etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab includes latent tuberculosis (TB) screening before initiating treatment and during therapy . The patient should also be monitored for signs of infection before, during and after treatment . Additionally, a CBC with differential and HBV screening should be performed. In certain patients, symptoms of heart failure, malignancy, hypersensitivity reactions, and lupus should be monitored.
Etanercept: The toxicity profile of etanercept is unknown; long-term human or animal studies have not been conducted. It was not shown to be mutagenic in vitro or in vivo studies.
Infliximab: The toxicity profile of infliximab is unknown. It also is not known if infliximab impairs fertility in humans.
Adalimumab: The toxicity profile of adalimumab is unknown; long-term human or animal studies have not been conducted. It was not shown to be mutagenic in vitro or in vivo studies.
Certolizumab pegol: The toxicity profile of certolizumab is unknown; long-term human or animal studies have not been conducted. It did not impair fertility in an in vivo mouse study.
Golimumab: The toxicity profile of golimumab is unknown; long-term human or animal studies have not been conducted. It did not impair fertility in an in vivo mouse study.
As with many medications, there must be interprofessional communication when it comes to the dispensing and monitoring of the various TNF alpha inhibitors. With inflammatory bowel disease and other autoimmune disorders, physicians and pharmacists must be aware of the treatment guidelines when making the decision to treat with TNF alpha inhibitors as opposed to other treatment options . Pharmacists, nurses and physicians must work together to ensure that proper dosing and dispensing protocols are in place and be aware of the possibility of adverse effects . For example, infliximab requires an infusion over a specific period of time, cannot be combined with other medications and there is the possibility of infusion-related reactions. Therefore, the healthcare team must work together to ensure patient safety, and the use of electronic medical records may be useful in this setting . Additionally, the healthcare team should be aware of the evolving nature of biosimilars as they relate to prescribing TNF alpha inhibitors and keep up-to-date on the available prescribing options .
|||New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis., Meroni PL,Valentini G,Ayala F,Cattaneo A,Valesini G,, Autoimmunity reviews, 2015 Sep [PubMed PMID: 25985765]|
|||Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis., Komaki Y,Yamada A,Komaki F,Kudaravalli P,Micic D,Ido A,Sakuraba A,, Journal of autoimmunity, 2017 May [PubMed PMID: 28209290]|
|||TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?, Rubbert-Roth A,Atzeni F,Masala IF,Caporali R,Montecucco C,Sarzi-Puttini P,, Autoimmunity reviews, 2017 Nov 3 [PubMed PMID: 29108829]|
|||Differentiating the efficacy of the tumor necrosis factor inhibitors., Haraoui B,, Seminars in arthritis and rheumatism, 2005 Apr [PubMed PMID: 15852248]|
|||Feldmann M,Maini RN, Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annual review of immunology. 2001; [PubMed PMID: 11244034]|
|||Gottlieb AB, Tumor necrosis factor blockade: mechanism of action. The journal of investigative dermatology. Symposium proceedings. 2007 May; [PubMed PMID: 17502861]|
|||Roach DR,Bean AG,Demangel C,France MP,Briscoe H,Britton WJ, TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. Journal of immunology (Baltimore, Md. : 1950). 2002 May 1; [PubMed PMID: 11971010]|
|||Moreland LW,Schiff MH,Baumgartner SW,Tindall EA,Fleischmann RM,Bulpitt KJ,Weaver AL,Keystone EC,Furst DE,Mease PJ,Ruderman EM,Horwitz DA,Arkfeld DG,Garrison L,Burge DJ,Blosch CM,Lange ML,McDonnell ND,Weinblatt ME, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of internal medicine. 1999 Mar 16 [PubMed PMID: 10075615]|
|||Maini R,St Clair EW,Breedveld F,Furst D,Kalden J,Weisman M,Smolen J,Emery P,Harriman G,Feldmann M,Lipsky P, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet (London, England). 1999 Dec 4 [PubMed PMID: 10622295]|
|||Mocci G,Marzo M,Papa A,Armuzzi A,Guidi L, Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. Journal of Crohn's [PubMed PMID: 23453887]|
|||Cheifetz A,Smedley M,Martin S,Reiter M,Leone G,Mayer L,Plevy S, The incidence and management of infusion reactions to infliximab: a large center experience. The American journal of gastroenterology. 2003 Jun; [PubMed PMID: 12818276]|
|||Anti-TNF therapy., Thalayasingam N,Isaacs JD,, Best practice & research. Clinical rheumatology, 2011 Aug [PubMed PMID: 22137924]|
|||Anti-TNF therapy: safety aspects of taking the risk., Rosenblum H,Amital H,, Autoimmunity reviews, 2011 Jul [PubMed PMID: 21570495]|
|||Clark M,Colombel JF,Feagan BC,Fedorak RN,Hanauer SB,Kamm MA,Mayer L,Regueiro C,Rutgeerts P,Sandborn WJ,Sands BE,Schreiber S,Targan S,Travis S,Vermeire S, American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul [PubMed PMID: 17631151]|
|||[PubMed PMID: 18467414]|
|||[PubMed PMID: 29491748]|
|||[PubMed PMID: 27479870]|